Depression is among the common psychiatric disorders, therefore the common pathways
and pathogenesis associated with depression is required to be studied. In few years, role of
5-hydroxytryptamine-1A/B (5-HT1A/B) receptors in depressive disorders have been revealed. Both
preclinical and clinical studies reported that the potential agonist and antagonist at 5-HT1A/B
receptors have significant modulatory effects in depression. However, the collective details
regarding the involvement of 5-HT1A/B receptors and the molecular pathways associated in
depression is lacking. Thus, the present review evidence the link between 5-HT1A/B receptors in
the brain and depression, the possible pathways involved and their alterations in depression.
Further, it reviews the preclinical evidences of 5-HT1A/B receptor modulators as antidepressant
agents and their effectiveness. The current review also details the clinical relevance of 5-HT1A/B
receptors etiopathogenesis of major depression in humans.
Growth differentiation factor 5: a neurotrophic factor with neuroprotective potential in Parkinson's disease.
Goulding SR, Anantha J, Collins LM, Sullivan AM, O'Keeffe GW
Neural regeneration research. 2022; 17(1): 38-44
Optogenetic activation of intracellular signaling based on light-inducible protein-protein homo-interactions.
Huang P, Zhao Z, Duan L
Neural regeneration research. 2022; 17(1): 25-30
Hyperglycemia in acute ischemic stroke: physiopathological and therapeutic complexity.
Ferrari F, Moretti A, Villa RF
Neural regeneration research. 2022; 17(2): 292-299
Cholesterol synthesis inhibition or depletion in axon regeneration.
Neural regeneration research. 2022; 17(2): 271-276
SYNGR4 and PLEKHB1 deregulation in motor neurons of amyotrophic lateral sclerosis models: potential contributions to pathobiology.
Marques RF, Duncan KE
Neural regeneration research. 2022; 17(2): 266-270